AIT Worldwide set to buy UK pharma forwarder Mach II Shipping
Fast-growing US 3PL AIT Worldwide is set to further expand in Europe with the purchase ...
The frightening speed with which the coronavirus appears to be spreading, and the Chinese authorities’ response to it, is having a predictable impact on transport systems – we have seen it before during similar events, but what is more profoundly disturbing is that there appears to be very little ability to accurately assess just vulnerable the rest of the world is to the disruptions. In the case of critical medicines, naturally, this is rather unsettling, as this report in Wired illustrates: “The biggest problem is that there is no publicly available information on what portion of which critical medicines originate in China, and specifically where those factories are located. Pharmaceutical companies consider such information to be proprietary.
“China has 15% of the world’s facilities that manufacture active pharmaceutical ingredients for 370 essential drugs, while the US has 21% of those facilities, according to the FDA. But the agency doesn’t know how much those facilities produce—if they produce anything at all.”
And given China’s central place in global supply chains, this is a story that could well be repeated across a whole range of verticals.
'I'm scared', says Boeing whistleblower, after two others suffer mysterious deaths
DSV could face $16m bill after helicopter is written off in haulage accident
Déjà vu as major ocean carriers scramble for tonnage and containers
FAK rate hikes holding, with strong demand into peak season predicted
Indian trade disrupted as port congestion forces liner services to skip calls
Shipper frustration as spot rates rise alongside demand, and cargo is rolled
Don't get too confident for Q2, market risks haven't disappeared, warns Yang Ming chief
Comment on this article